Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BGB-16673 |
Synonyms | |
Therapy Description |
BGB-16673 is a proteolysis-targeted chimera (PROTAC) that binds to Bruton's tyrosine kinase (BTK) and targets it for degradation, potentially leading to growth inhibition of BTK-expressing tumor cells (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BGB-16673 | BGB16673|BGB 16673 | BTK inhibitor 37 | BGB-16673 is a proteolysis-targeted chimera (PROTAC) that binds to Bruton's tyrosine kinase (BTK) and targets it for degradation, potentially leading to growth inhibition of BTK-expressing tumor cells (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05006716 | Phase I | BGB-16673 | A Phase 1 Dose-Escalation and Expansion Study of BGB-16673 in Patients With B-Cell Malignancies | Recruiting | USA | TUR | SWE | ITA | GBR | FRA | ESP | DEU | CAN | BRA | AUS | 3 |